How Obamacare's $20 Billion Bonanza Is Bombing

Tucked away inside Obamacare are 18 pages that could create a new $20 billion-per-year market. The section of Obamacare known as the "Biologics Price Competition and Innovation Act'' authorized the creation of a pathway to approval in the U.S. for biosimilar products. These biosimilars are basically generic versions of biologics, which are drugs derived from living organisms.

While controversy continues to rage about the benefits and costs of much of Obamacare, the consensus is that the introduction of biosimilars into the U.S. should be a big plus. However, three years after passage of the act, little progress has been made. Here's why.

Bonanza
Increased use of generic drugs has helped tremendously in controlling prescription drug spending. The nation's largest pharmacy benefits manager, Express Scripts (NASDAQ: ESRX  ) , says that less expensive generics contributed to lower spending last year on treatments for common diseases such as high cholesterol. This marked the first time in two decades that these costs were reduced.

Despite this good news, total prescription drug spending still increased by 2.7%. Why? Americans spent more on specialty drugs, which are used in the treatment of diseases including cancer, hepatitis C, and rheumatoid arthritis. Generic alternatives aren't available for many of these drugs, in part because some of them are biologics. The U.S. had no approval process for biosimilar versions of these biologic drugs before 2009.

However, Obamacare includes provisions that authorized the secretary of Health and Human Services to establish a pathway for approval for biosimilars. The measure was one of the few parts of the law that garnered broad bipartisan support in the House and Senate. Both major political parties appeared to realize the potential for biosimilars to help control medication costs over the long run.    

IMS Health projects that the U.S. market for biosimilars should generate $20 billion annually by 2020. This baseline assumes that biosimilars will comprise 8% of the total biologics market by that point. IMS Health thinks that growth could possibly surpass this level, with biosimilar sales of more than $25 billion by 2020.

Express Scripts seems poised to be a winner with the growth of biosimilars. Like other pharmacy benefit managers, or PBMs, the company makes higher profits on generic drugs compared to brand drugs. While biosimilars won't be as profitable as these generics, increased availability of biosimilars could open up new avenues for Express Scripts to boost earnings.

Companies that successfully launch biosimilars should also reap the benefits of the new approval pathway. IMS Health's study published in late 2011 about the potential for this new market highlighted Teva Pharmaceuticals (NYSE: TEVA  ) as a prime example of one of these potential success stories. Teva currently ranks as one of the leading makers of generic drugs.

Bombs
The heralded bonanza hasn't materialized yet, though. While a handful of "follow-on biologics" have been approved by the Food and Drug Administration, so far no biosimilars have gained approval through the pathway authorized by Obamacare.

Teva did get FDA clearance for marketing Neutroval, a biosimilar for Amgen's Neupogen. However, that approval came through the already-established Biologic License Application, or BLA, process rather than the newer biosimilar pathway introduced in Obamacare.

What about the Teva program touted by IMS Health as "poised to compete" in the new world of biosimilars -- development of a knock-off of Rituxan? In late 2012, Teva and partner Lonza stopped late-stage development for the drug. The companies stated that they were "evaluating the path forward for a Phase III trial based on the latest changes in the regulatory environment."Lonza CEO Richard Ridinger told Reuters that the cost of developing biosimilars was "considerably more" than first anticipated. 

Part of the problem is that the FDA has moved in slow motion. As of April 2013, only four draft guidance documents have been released. Regulatory uncertainty has been a primary reason that no company has even applied yet for biosimilar approval through the new pathway.

Another issue is that current makers of blockbuster biologic drugs aren't going down without a fight. AbbVie (NYSE: ABBV  ) , which makes the world's top-selling drug Humira, petitioned the FDA last year to prevent approvals of biosimilars for Humira because the agency would have to use the company's trade secrets to do so. The company also plans to battle against potential competitors for possible patent violations.

Some roadblocks for biosimilars can't be easily solved. Manufacturing the drugs is complex and requires large investments. Companies entering the biosimilar market face significant technological and financial hurdles.

Beyond the minefield
So far, the introduction of biosimilars in the U.S has not been so good. However, the problems are not insurmountable.

Most importantly, the federal government needs to get its act together. Clear guidelines for the biosimilar approval process would enable more companies to move forward with seeking approval for biosimilars. The potential benefits can still be obtained, with investors and the U.S. public emerging as winners. For now, though, the hoped-for $20 billion biosimilar bonanza is bombing.

Obamacare will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2468997, ~/Articles/ArticleHandler.aspx, 10/24/2014 4:18:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 16,677.90 216.58 1.32%
S&P 500 1,950.82 23.71 1.23%
NASD 4,452.79 69.95 1.60%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/23/2014 3:59 PM
ESRX $73.06 Up +0.06 +0.08%
Express Scripts CAPS Rating: ****
TEVA $53.60 Up +0.39 +0.73%
Teva Pharmaceutica… CAPS Rating: *****

Advertisement